Want to see KRYS full AI Analyst Report?
KRYS Stock Chart & Stats
$274.21
-$3.73(-2.33%)
At close: 4:00 PM EST
$274.21
-$3.73(-2.33%)
Day’s Range― - ―
52-Week Range$130.50 - $382.54
Previous CloseN/A
Volume44.50K
Average Volume (3M)369.91K
Market Cap
$10.46B
Enterprise Value$7.07K
Total Cash (Recent Filing)$823.40M
Total Debt (Recent Filing)$9.11M
Price to Earnings (P/E)45.8
Beta0.73
Next Earnings
Aug 10, 2026EPS Estimate
1.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.75
Shares Outstanding29,479,755
10 Day Avg. Volume352,225
30 Day Avg. Volume369,912
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)5.85
Price to Sales (P/S)18.34
P/FCF Ratio37.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$358.89Price Target Upside30.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)7.61
Revenue Forecast (FY)$514.43M
Bulls Say, Bears Say
Bulls Say
Very High Gross Margins And ProfitabilityKrystal's persistently high gross margins (≈93–95%) and recent net margin (~53%) reflect a scalable manufacturing and pricing profile for VYJUVEK. Durable margin structure supports reinvestment in pipeline, funds commercialization and insulates cash flow against moderate pricing pressure over the next 2–6 months.
Strong Cash Generation And Healthy Cash ConversionConsistent operating cash flow and near-net-income free cash flow give Krystal financial flexibility to fund launches, late‑stage trials and commercialization without needing near-term external financing. Strong FCF reduces execution risk and supports a multi-quarter investment horizon for growth initiatives.
Commercial Traction And Concentrated Market Share For VYJUVEKRapid prescriber adoption, extensive reimbursement approvals and ~60% share of a limited patient pool indicate durable commercial penetration in a rare-disease market. This entrenched position supports recurring revenue and provides a strong base for international rollout and uptake over coming quarters.
Bears Say
Quarter-to-quarter Revenue UnpredictabilityPayer-driven insurer switchovers and maintenance dosing patterns produce structural revenue cadence variability. This reduces near-term visibility for planning and can complicate production and inventory decisions, making multi-quarter revenue forecasting and resource allocation more challenging.
European Pricing And Reimbursement UncertaintyPending reimbursements and pricing negotiations in major European markets are material to international revenue. Outcomes and timing in Germany, France and other countries will materially affect access and margins; protracted negotiations could delay revenue realization and constrain European commercialization over the next 6–12 months.
Historical Volatility And Durability RiskAlthough recent profitability is strong, the company has a short-run track record with prior multi-year losses and a marked slowdown in 2025. This history signals execution and growth volatility risk if commercial or regulatory setbacks occur, limiting confidence in steady multi-quarter expansion.
Krystal Biotech News
KRYS FAQ
What was Krystal Biotech’s price range in the past 12 months?
Krystal Biotech lowest stock price was $130.50 and its highest was $382.54 in the past 12 months.
What is Krystal Biotech’s market cap?
Krystal Biotech’s market cap is $10.46B.
When is Krystal Biotech’s upcoming earnings report date?
Krystal Biotech’s upcoming earnings report date is Aug 10, 2026 which is in 21 days.
How were Krystal Biotech’s earnings last quarter?
Krystal Biotech released its earnings results on May 04, 2026. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.34.
Is Krystal Biotech overvalued?
According to Wall Street analysts Krystal Biotech’s price is currently Undervalued.
Does Krystal Biotech pay dividends?
Krystal Biotech does not currently pay dividends.
What is Krystal Biotech’s EPS estimate?
Krystal Biotech’s EPS estimate is 1.75.
How many shares outstanding does Krystal Biotech have?
Krystal Biotech has 29,479,755 shares outstanding.
What happened to Krystal Biotech’s price movement after its last earnings report?
Krystal Biotech reported an EPS of $1.83 in its last earnings report, beating expectations of $1.49. Following the earnings report the stock price went up 7.86%.
Which hedge fund is a major shareholder of Krystal Biotech?
Currently, no hedge funds are holding shares in KRYS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Krystal Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$358.89 (30.88% Upside)
$358.89 (30.88% Upside)
Blogger Sentiment
Bullish
KRYS Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 74.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 9.7%
Last 30 Days ▲ 9.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
136.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
30.02%
Trailing 12-Months
Company Description
Krystal Biotech
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
KRYS Stock 12 Month Forecast
Average Price Target
$358.89
▲(30.88% Upside)
Technical Analysis
Ownership Overview
11.14% Insiders
30.42% Mutual Funds
0.47% Other Institutional Investors
31.07% Public Companies and Individual Investors